Annual Report · 10-K
CRISPR Therapeutics AG
CRSPNASDAQEQUITYCurrent
Annual Report
Company context
CRISPR Therapeutics and Vertex established a strategic research collaboration in 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to address the underlying genetic causes of human disease. CASGEVY is the first approved therapy to emerge from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗